The future of AI drug discovery & development in immunology and GPCR research
pharmaphorum
SEPTEMBER 16, 2022
A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. A notable issue with clinical trials is the homogeneity of the patient database. What, then, is the solution?
Let's personalize your content